As part of the multicenter CONCEPT trial, Dr. Goy tested the efficacy and safety of denileukin diftitox, a genetically engineered fusion protein that targets cancers that express the interleukin-2 receptor. The drug was tested head-to-head against the standard "CHOP" (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regimen in a Phase II study in which the patients receiving the new drug were also treated with CHOP. The study group consisted of patients newly diagnosed with aggressive T-cell lymphomas. Researchers found the combination therapy effective, with a 68% overall response rate and 57% complete response rate. As a result, they are starting a multicenter comparison study.
About the John Theurer Cancer Center at Hackensack University Medical Center
The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of
|SOURCE John Theurer Cancer Center|
Copyright©2010 PR Newswire.
All rights reserved